Acumen Pharmaceuticals, Inc.

NASDAQ:ABOS

Biotechnology

Healthcare
$2.29 +0.67%

+$0.02 today

Market cap
$165.63M
Beta
0.35
P/E (TTM)
-1.3
EPS (TTM)
-$1.79
52W Low $1.10High $3.60

Volume 0.81M

Average 0.40M

Returns on capital

Acumen Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-172.3%

avg -29.6%

ROIC

-121.7%

avg -54.3%

ROA

-98.8%

avg -49.8%

Analysis

ROA is currently the strongest return metric at -98.8% versus its period average of -49.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Daniel J. O'Connell

Chief Executive Officer & DirectorUSD 972.75K56——

James Doherty

President & Chief Development OfficerUSD 764.37K58——

Derek Meisner

Chief Legal Officer & Corporate SecretaryUSD 752.95K55——

Matt Zuga

Chief Financial Officer & Chief Business OfficerUSD 681.78K—304.92K0.50%

Russell Barton

Chief Operating OfficerUSD 223.68K67205.09K0.34%

Grant A. Krafft

Co-FounderUSD 42K———

William L. Klein

Co-FounderUSD 42K———

Caleb E. Finch

Co-FounderUSD 42K———

Alex Braun

Vice President & Head of Investor Relations————

Kelly Carranza

Senior Vice President of Finance & Accounting and Corporate Controller————

Compensation is shown in the reported currency; data updated Oct 3, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 22, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

48

$625,430.93

Net Transaction Value

−$625,430.93

Net selling

Most Active

Meisner Derek M

16 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jun 17, 26

Porter Derrell

Direct

Sell$30.3K
Jun 16, 26

Porter Derrell

Direct

Sell$29.8K
Jun 15, 26

Porter Derrell

Direct

Sell$15.1K
Jun 9, 26

Fountain Nathan B

Direct

Sell$14.3K
Mar 6, 26

Meisner Derek M

Direct

Sell$6.8K
Feb 27, 26

Meisner Derek M

Direct

Sell$28.3K
Jan 28, 26

Meisner Derek M

Direct

Sell$8K
Jan 26, 26

Meisner Derek M

Direct

Sell$45.3K
Jan 23, 26

Meisner Derek M

Direct

Sell$10.7K
Jan 22, 26

OConnell Daniel Joseph

Direct

Sell$5.1K

1–10 of 48

Summary

Insiders reported 0 buys worth $0.00 and 48 sells worth $625,430.93 over the last 12 months. That adds up to net selling of $625,430.93. Meisner Derek M was the most active insider with 16 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Acumen Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ABOS's management, answered from reported figures.

Who manages ABOS?

Acumen Pharmaceuticals, Inc. (ABOS) lists 10 active executives. The top listed executive is Derek Meisner, Chief Legal Officer & Corporate Secretary.

Are ABOS insiders buying or selling?

Recent insider activity shows net buying of $74.71M.